# Bronchiectasis Treatment and Management: Recent Clinical Trials and Literature Review
 
**Search Databases:** Europe PMC, ClinicalTrials.gov, NEJM, Nature, The Lancet  
**Focus:** Recent clinical trials and research in bronchiectasis treatment and management

---

## Executive Summary

This review identified **20 recent research papers** from Europe PMC (2025-2026) and **48 currently recruiting clinical trials** from ClinicalTrials.gov focused on bronchiectasis treatment and management. Key therapeutic areas include antifibrotic agents, airway clearance techniques, antimicrobial therapies, pulmonary rehabilitation, and novel biologics.

---

## Recent Literature from Europe PMC (2025-2026)

### 1. Antifibrotic Therapies

#### MIST Study - Pirfenidone Inhalation for Progressive Pulmonary Fibrosis
- **PMCID:** [PMC12742111](https://europepmc.org/articles/PMC12742111)
- **PMID:** 41448793
- **DOI:** 10.1136/bmjresp-2024-003059
- **Study Type:** Phase 2b, double-blind, randomized, placebo-controlled trial
- **Intervention:** AP01 (pirfenidone solution for inhalation) 100mg or 50mg BID vs placebo
- **Registration:** NCT06329401
- **Key Points:** Inhaled pirfenidone may offer improved tolerability vs oral administration

#### DPP-1 Inhibitors Meta-Analysis
- **PMCID:** [PMC12659227](https://europepmc.org/articles/PMC12659227)
- **PMID:** 41299471
- **DOI:** 10.1186/s12931-025-03407-2
- **Study Type:** GRADE-assessed meta-analysis of RCTs
- **Conclusion:** DPP-1 inhibitors reduce exacerbation frequency without compromising safety

### 2. Integrated Traditional Chinese Medicine and Western Medicine

#### TCM-WM Integration Review
- **PMCID:** [PMC12801566](https://europepmc.org/articles/PMC12801566)
- **PMID:** 41535950
- **DOI:** 10.1186/s13020-026-01324-0
- **Study Type:** Comprehensive review
- **Key Findings:**
  - Integrated TCM-WM therapy significantly alleviates symptoms
  - Improves lung function and immune regulation
  - Enhances quality of life
  - Provides personalized, multidimensional paradigm

### 3. Neutrophil Dysfunction and Emerging Targeted Therapies

#### Neutrophil Dysfunction in Bronchiectasis Review
- **PMCID:** [PMC12558659](https://europepmc.org/articles/PMC12558659)
- **PMID:** 41114944
- **DOI:** 10.5826/mrm.2025.1034
- **Study Type:** Narrative review (2020-2025)
- **Emerging Therapies:**
  - DPP-1 inhibitors (e.g., brensocatib) - WILLOW and ASPEN trials
  - CXCR2 antagonists
  - PI3K inhibitors
  - NET-targeting therapies
- **Biomarkers:**
  - Neutrophil elastase activity
  - Sputum procalcitonin
  - NMR-derived metabolic phenotypes
- **Conclusion:** Targeting neutrophil dysfunction offers promising disease-modifying therapy

### 4. CFTR Modulators in Non-CF Bronchiectasis

#### CFTR Modulators Editorial
- **PMCID:** [PMC12581163](https://europepmc.org/articles/PMC12581163)
- **PMID:** 41189579
- **DOI:** 10.1183/23120541.00593-2025
- **Study Type:** Editorial
- **Key Points:**
  - May improve outcomes in patients with one CFTR mutation
  - Additional studies needed to confirm preliminary findings
  - Represents potential for precision medicine approach

### 5. Aspergillus-Related Airway Diseases

#### ABPA and Aspergillus-Related Diseases in Bronchiectasis
- **PMCID:** [PMC12780404](https://europepmc.org/articles/PMC12780404)
- **PMID:** 41522133
- **DOI:** 10.21037/jtd-2025-1548
- **Study Type:** Narrative review
- **Key Findings:**
  - ABPA affects ~4% of bronchiectasis patients
  - Aspergillus sensitization and chronic infection may affect up to 30%
  - Associated with worse clinical outcomes and increased exacerbations
  - Routine screening recommended with A. fumigatus-IgE
- **Management:** Systemic glucocorticoids or triazole antifungals

### 6. Pulmonary Rehabilitation and Singing for Lung Health

#### Singing for Lung Health Post-PR Feasibility Trial
- **PMCID:** [PMC12778336](https://europepmc.org/articles/PMC12778336)
- **PMID:** 41494697
- **DOI:** 10.1136/bmjresp-2025-003236
- **Study Type:** Multicentre, mixed-methods RCT
- **Trial Registration:** ISRCTN11056049
- **Conclusion:** Definitive RCT appears feasible with acceptable uptake

### 7. Additional Notable Publications

#### Telemedicine in Chronic Lung Disease Management
- **PMCID:** [PMC12800465](https://europepmc.org/articles/PMC12800465)
- **PMID:** 41429145
- **DOI:** 10.3904/kjim.2025.081
- **Focus:** Home spirometry, wearable devices, telerehabilitation

#### Global Research Trends - Bibliometric Analysis
- **PMCID:** [PMC12780437](https://europepmc.org/articles/PMC12780437)
- **PMID:** 41522117
- **DOI:** 10.21037/jtd-2025-528
- **Key Findings:** Bronchiectasis evolved from orphan to common disease with increasing research output

#### Precision Medicine Advances
- **PMCID:** [PMC12692219](https://europepmc.org/articles/PMC12692219)
- **PMID:** 41373404
- **DOI:** 10.3390/ijms262311243

#### Managing Breathlessness in Advanced Respiratory Disease
- **PMCID:** [PMC12621120](https://europepmc.org/articles/PMC12621120)
- **PMID:** 41257188
- **DOI:** 10.1183/23120541.00205-2025

#### Efficacy of Bronchial Artery Embolization
- **PMCID:** [PMC12701884](https://europepmc.org/articles/PMC12701884)
- **PMID:** 41389100
- **DOI:** 10.1186/s42155-025-00627-x

#### Antifibrotic Strategies for ILD in Rheumatoid Arthritis
- **PMCID:** [PMC12707150](https://europepmc.org/articles/PMC12707150)
- **PMID:** 41409437
- **DOI:** 10.2147/oarrr.s561159

#### Pirfenidone for COVID-19 ILAs Meta-Analysis
- **PMCID:** [PMC12789973](https://europepmc.org/articles/PMC12789973)
- **PMID:** 41522210
- **DOI:** 10.1155/carj/8812779

#### FeNO Monitoring in Severe Asthma with Bronchiectasis Comorbidity
- **PMID:** 41534721
- **DOI:** 10.1016/j.rmed.2026.108647

---

## Currently Recruiting Clinical Trials (ClinicalTrials.gov)

### Phase 3 Trials

#### NCT06443658 - Hypertonic Saline with ELTGOL Physiotherapy
- **Title:** Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique
- **Status:** RECRUITING
- **Sponsor:** Institut d'Investigació Biomèdica de Girona (Spain)
- **Start Date:** June 2024
- **Link:** https://clinicaltrials.gov/study/NCT06443658

#### NCT06660992 - HSK31858 Efficacy Study
- **Title:** A Study to Assess the Efficacy and Safety of HSK31858
- **Status:** RECRUITING
- **Sponsor:** Haisco Pharmaceutical Group (China)
- **Start Date:** September 2024
- **Link:** https://clinicaltrials.gov/study/NCT06660992

#### NCT06160713 - Itraconazole for Chronic Aspergillus Infection
- **Title:** Oral Itraconazole vs Standard Care for Chronic Aspergillus Infection
- **Status:** RECRUITING
- **Sponsor:** PGIMER, Chandigarh (India)
- **Start Date:** December 2023
- **Link:** https://clinicaltrials.gov/study/NCT06160713

### Phase 4 Trials

#### NCT06242795 - Hypertonic Saline in NCFB
- **Status:** RECRUITING
- **Sponsor:** University of North Carolina, Chapel Hill (USA)
- **Start Date:** October 2024
- **Link:** https://clinicaltrials.gov/study/NCT06242795

#### NCT06551337 - Vitamin D Replacement
- **Status:** RECRUITING
- **Sponsor:** Queen Mary Hospital, Hong Kong
- **Start Date:** April 2024
- **Link:** https://clinicaltrials.gov/study/NCT06551337

#### NCT06209047 - Bronchoscopic Antibiotics
- **Title:** Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation
- **Status:** RECRUITING
- **Sponsor:** Assiut University (Egypt)
- **Start Date:** October 2023
- **Link:** https://clinicaltrials.gov/study/NCT06209047

#### NCT07114120 - Traditional Chinese Medicine
- **Title:** Bailing Capsules Combined With Guben Kechuan Granules
- **Status:** RECRUITING
- **Sponsor:** Second Affiliated Hospital, Zhejiang University (China)
- **Start Date:** July 2025
- **Link:** https://clinicaltrials.gov/study/NCT07114120

### Phase 2 Trials

#### NCT06559150 - Ensifentrine
- **Status:** RECRUITING
- **Sponsor:** Verona Pharma plc
- **Start Date:** September 2024
- **Link:** https://clinicaltrials.gov/study/NCT06559150

#### NCT06166056 - CHF6333 Inhaled Therapy
- **Title:** Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333
- **Status:** RECRUITING (Phase 1/2)
- **Sponsor:** Chiesi Farmaceutici
- **Start Date:** November 2023
- **Link:** https://clinicaltrials.gov/study/NCT06166056

#### NCT06368804 - Pseudomonas Aeruginosa Eradication
- **Title:** Comparison of Two Antibiotic Regimens for Early PA Infection
- **Status:** RECRUITING
- **Sponsor:** Centre Hospitalier Intercommunal Creteil (France)
- **Start Date:** September 2024
- **Link:** https://clinicaltrials.gov/study/NCT06368804

#### NCT06663176 - RESP30X Nitric Oxide Formulations
- **Title:** Nebulised RESP30X NO in NCFB with Pseudomonas Aeruginosa
- **Status:** RECRUITING (Phase 1/2)
- **Sponsor:** Thirty Respiratory Limited (UK)
- **Start Date:** October 2024
- **Link:** https://clinicaltrials.gov/study/NCT06663176

#### NCT07063290 - COMBO Endoscopy Oropharyngeal Airway
- **Status:** RECRUITING
- **Sponsor:** Zhejiang University (China)
- **Start Date:** June 2025
- **Link:** https://clinicaltrials.gov/study/NCT07063290

### Phase 1 Trials

#### NCT06603246 - GDC-6988 for Muco-obstructive Disease
- **Title:** Safety and Effects of Inhaled GDC-6988
- **Status:** RECRUITING
- **Sponsor:** Genentech, Inc. (USA)
- **Start Date:** November 2024
- **Link:** https://clinicaltrials.gov/study/NCT06603246

### Major Observational Studies and Registries

#### NCT01822834 - Bronchiectasis and NTM Research Registry
- **Status:** RECRUITING (ongoing since 2008)
- **Sponsor:** COPD Foundation (USA)
- **Study Type:** Patient registry
- **Link:** https://clinicaltrials.gov/study/NCT01822834

#### NCT03791086 - BRIDGE Study
- **Title:** Bronchiectasis Research Involving Databases, Genomics and Endotyping
- **Status:** RECRUITING
- **Sponsor:** University of Dundee (UK)
- **Start Date:** November 2019
- **Link:** https://clinicaltrials.gov/study/NCT03791086

#### NCT06798077 - Chronic Airway Disease and Multimorbidity Cohort
- **Status:** RECRUITING
- **Sponsor:** China-Japan Friendship Hospital (China)
- **Start Date:** February 2025
- **Link:** https://clinicaltrials.gov/study/NCT06798077

#### NCT04538859 - Hong Kong Bronchiectasis Cohort
- **Title:** Factors Related to Exacerbation and Mortality
- **Status:** RECRUITING
- **Sponsor:** Chinese University of Hong Kong
- **Start Date:** August 2020
- **Link:** https://clinicaltrials.gov/study/NCT04538859

#### NCT05604495 - CF Screening in Chinese Adults
- **Title:** Screening for CF and CF-Related Disorders
- **Status:** RECRUITING
- **Sponsor:** Shanghai Pulmonary Hospital (China)
- **Start Date:** September 2022
- **Link:** https://clinicaltrials.gov/study/NCT05604495

#### NCT02779478 - Lung Microbiome in NTM Bronchiectasis
- **Status:** RECRUITING
- **Sponsor:** NYU Langone Health (USA)
- **Start Date:** October 2014
- **Link:** https://clinicaltrials.gov/study/NCT02779478

#### NCT02527486 - Seoul National University Airway Registry
- **Status:** RECRUITING (ongoing since 2011)
- **Sponsor:** Seoul National University Hospital (South Korea)
- **Link:** https://clinicaltrials.gov/study/NCT02527486

### Airway Clearance and Pulmonary Rehabilitation Trials

#### NCT06393257 - Oscillation and Lung Expansion
- **Title:** Airway Clearance Technique of Oscillation and Lung Expansion
- **Status:** RECRUITING
- **Sponsor:** Shanghai Pulmonary Hospital (China)
- **Start Date:** September 2023
- **Link:** https://clinicaltrials.gov/study/NCT06393257

#### NCT03561818 - Home vs Hospital-based Pulmonary Rehabilitation
- **Status:** RECRUITING
- **Sponsor:** Istanbul Medipol University Hospital (Turkey)
- **Start Date:** June 2018
- **Link:** https://clinicaltrials.gov/study/NCT03561818

#### NCT06304207 - Telehealth and Onsite Maintenance Exercise
- **Status:** RECRUITING
- **Sponsor:** MGH Institute of Health Professions (USA)
- **Start Date:** September 2023
- **Link:** https://clinicaltrials.gov/study/NCT06304207

#### NCT06926881 - OLE Therapy in Home Care
- **Status:** RECRUITING
- **Sponsor:** Delve Health
- **Start Date:** May 2025
- **Link:** https://clinicaltrials.gov/study/NCT06926881

#### NCT06017739 - Expiratory Flow Accelerator vs EFA + High Flow
- **Status:** RECRUITING
- **Sponsor:** Azienda Socio Sanitaria Territoriale della Valle Olona (Italy)
- **Start Date:** October 2023
- **Link:** https://clinicaltrials.gov/study/NCT06017739

### Novel Antimicrobial and Anti-inflammatory Interventions

#### NCT05407792 - Oral Staphylococcus Albicans Tablets
- **Status:** RECRUITING
- **Sponsor:** Qianfoshan Hospital (China)
- **Start Date:** June 2022
- **Link:** https://clinicaltrials.gov/study/NCT05407792

#### NCT06726356 - Bronchoalveolar Lavage with Acetylcysteine
- **Status:** RECRUITING
- **Sponsor:** First Affiliated Hospital of Ningbo University (China)
- **Start Date:** August 2024
- **Link:** https://clinicaltrials.gov/study/NCT06726356

#### NCT06760273 - Long-term Inhaled Tobramycin (ERASE II)
- **Title:** Long-term Impact for Pseudomonas Aeruginosa Eradication
- **Status:** RECRUITING
- **Sponsor:** Shanghai Pulmonary Hospital (China)
- **Start Date:** October 2024
- **Link:** https://clinicaltrials.gov/study/NCT06760273

### Diagnostic and Assessment Studies

#### NCT06631261 - 6-Minute Stepper Test
- **Title:** Cardiopulmonary Responses vs Healthy Controls
- **Status:** RECRUITING
- **Sponsor:** Hacettepe University (Turkey)
- **Start Date:** September 2024
- **Link:** https://clinicaltrials.gov/study/NCT06631261

#### NCT06528418 - VOC Biomarkers in Exhaled Breath
- **Status:** RECRUITING
- **Sponsor:** ChromX Health
- **Start Date:** June 2024
- **Link:** https://clinicaltrials.gov/study/NCT06528418

#### NCT07102589 - SWEEP: Shuttle Walking Test
- **Status:** RECRUITING
- **Sponsor:** Seoul National University Bundang Hospital (South Korea)
- **Start Date:** June 2025
- **Link:** https://clinicaltrials.gov/study/NCT07102589

#### NCT05741697 - HFNC in Management of Exacerbations
- **Title:** High Flow Nasal Cannula
- **Status:** RECRUITING
- **Sponsor:** Assiut University (Egypt)
- **Start Date:** March 2023
- **Link:** https://clinicaltrials.gov/study/NCT05741697

### Comorbidities and Special Populations

#### NCT05783869 - Cardiovascular Comorbidities
- **Status:** RECRUITING
- **Sponsor:** Assiut University (Egypt)
- **Start Date:** March 2023
- **Link:** https://clinicaltrials.gov/study/NCT05783869

#### NCT06344000 - Disease Progression and Nutritional Status
- **Status:** RECRUITING
- **Sponsor:** Union Hospital, Huazhong University (China)
- **Start Date:** April 2024
- **Link:** https://clinicaltrials.gov/study/NCT06344000

#### NCT07060079 - Sleep Disordered Breathing Assessment
- **Status:** RECRUITING
- **Sponsor:** University College London (UK)
- **Start Date:** April 2025
- **Link:** https://clinicaltrials.gov/study/NCT07060079

#### NCT06625944 - Viral Infections in Chronic Lung Disease
- **Status:** RECRUITING
- **Sponsor:** Imperial College London (UK)
- **Start Date:** November 2024
- **Link:** https://clinicaltrials.gov/study/NCT06625944

#### NCT07192705 - Health Impact of NTM Pulmonary Disease
- **Status:** RECRUITING
- **Sponsor:** University College London (UK)
- **Start Date:** August 2025
- **Link:** https://clinicaltrials.gov/study/NCT07192705

### Primary Ciliary Dyskinesia and Genetic Studies

#### NCT00807482 - Pathogenesis of PCD Lung Disease
- **Status:** RECRUITING (ongoing since 2004)
- **Sponsor:** University of North Carolina, Chapel Hill (USA)
- **Link:** https://clinicaltrials.gov/study/NCT00807482

#### NCT03606200 - Swiss PCD Registry
- **Status:** RECRUITING (ongoing since 2013)
- **Sponsor:** University of Bern (Switzerland)
- **Link:** https://clinicaltrials.gov/study/NCT03606200

### Imaging and Research Tools

#### NCT02279329 - Helium-3 and Xenon-129 MRI
- **Status:** RECRUITING (ongoing since 2009)
- **Sponsor:** Dr. Grace Parraga (Canada)
- **Start Date:** May 2009
- **Link:** https://clinicaltrials.gov/study/NCT02279329

#### NCT03839992 - Detection of Small Airways Obstruction in CF
- **Status:** RECRUITING
- **Sponsor:** Gelb, Arthur F., M.D. (USA)
- **Start Date:** April 2018
- **Link:** https://clinicaltrials.gov/study/NCT03839992

### Intervention Studies

#### NCT06326957 - SELF-BREATHE Internet-based Intervention
- **Title:** Reducing Chronic Breathlessness
- **Status:** RECRUITING
- **Sponsor:** King's College Hospital NHS Trust (UK)
- **Start Date:** July 2024
- **Link:** https://clinicaltrials.gov/study/NCT06326957

#### NCT06670937 - BARriers in IgG-Pathogen Interactions
- **Status:** RECRUITING
- **Sponsor:** University Hospital, Tours (France)
- **Start Date:** December 2024
- **Link:** https://clinicaltrials.gov/study/NCT06670937

#### NCT06361121 - Regional Anesthesia Techniques
- **Title:** MTP to Pleura Block vs Thoracic Paravertebral Block
- **Status:** RECRUITING
- **Sponsor:** Fayoum University Hospital (Egypt)
- **Start Date:** March 2024
- **Link:** https://clinicaltrials.gov/study/NCT06361121

### Disease Progression and Mechanisms

#### NCT05731427 - Mechanism Affecting Progression
- **Status:** RECRUITING
- **Sponsor:** Union Hospital, Huazhong University (China)
- **Start Date:** February 2021
- **Link:** https://clinicaltrials.gov/study/NCT05731427

#### NCT04966793 - Microbial Colonization and Adaptive Evolution
- **Status:** RECRUITING
- **Sponsor:** Second Affiliated Hospital, Zhejiang University (China)
- **Start Date:** February 2020
- **Link:** https://clinicaltrials.gov/study/NCT04966793

#### NCT03120481 - Controls for Respiratory Diseases
- **Status:** RECRUITING (ongoing since 2017)
- **Sponsor:** Seoul National University Hospital (South Korea)
- **Link:** https://clinicaltrials.gov/study/NCT03120481

### Pediatric Studies

#### NCT07121218 - Physical Fitness Level Determination
- **Status:** RECRUITING
- **Sponsor:** Melis Usul
- **Start Date:** August 2025
- **Link:** https://clinicaltrials.gov/study/NCT07121218

#### NCT07104942 - Expiratory Muscle Strength Effects
- **Status:** RECRUITING
- **Sponsor:** Nisanur Tutuş
- **Start Date:** August 2025
- **Link:** https://clinicaltrials.gov/study/NCT07104942

---

## Key Therapeutic Areas and Trends

### 1. **Antifibrotic Agents**
- Pirfenidone (oral and inhaled formulations)
- DPP-1 inhibitors showing significant exacerbation reduction
- Potential application across progressive fibrotic lung diseases

### 2. **Antimicrobial Strategies**
- Inhaled antibiotics for Pseudomonas aeruginosa eradication
- Early intervention protocols
- Long-term suppressive therapy
- Novel nitric oxide formulations

### 3. **Airway Clearance Techniques**
- Hypertonic saline (multiple Phase 3/4 trials)
- Oscillation and lung expansion devices
- Integration with physiotherapy techniques (ELTGOL)
- Home-based vs hospital-based approaches

### 4. **Immunomodulation and Anti-inflammatory**
- DPP-1 inhibitors
- CXCR2 antagonists
- PI3K inhibitors
- Neutrophil elastase targeting

### 5. **Mucoactive and Bronchodilator Therapies**
- Ensifentrine (PDE3/4 inhibitor)
- CHF6333 inhaled therapy
- GDC-6988 for muco-obstructive disease

### 6. **Precision Medicine Approaches**
- CFTR modulators for patients with CFTR mutations
- Genetic screening and registry studies
- Biomarker-guided therapy
- Microbiome profiling

### 7. **Pulmonary Rehabilitation**
- Telehealth and remote monitoring
- Singing for lung health
- Exercise maintenance programs
- Nutritional interventions

### 8. **Traditional and Complementary Medicine**
- TCM-Western medicine integration
- Herbal formulations (Bailing capsules, Guben Kechuan granules)
- Acupuncture and holistic approaches

### 9. **Aspergillus and Fungal Management**
- Screening protocols
- Long-term antifungal therapy (itraconazole)
- ABPA recognition and treatment

### 10. **Digital Health and Remote Monitoring**
- Home spirometry
- Wearable devices
- Mobile health applications
- Telemedicine platforms

---

## Geographic Distribution of Active Trials

- **China:** 13 trials (largest contributor)
- **USA:** 8 trials
- **UK:** 5 trials
- **Egypt:** 4 trials
- **Turkey:** 2 trials
- **South Korea:** 2 trials
- **France:** 2 trials
- **Spain, India, Italy, Hong Kong, Switzerland, Canada:** 1 trial each

---

## Conclusions

1. **Therapeutic Innovation:** Significant progress in antifibrotic agents (DPP-1 inhibitors, pirfenidone) with robust Phase 2/3 evidence showing exacerbation reduction

2. **Antimicrobial Evolution:** Shift toward early eradication protocols, inhaled antibiotics, and novel delivery systems (nitric oxide formulations)

3. **Personalized Medicine:** Growing emphasis on genetic screening, biomarkers, and targeted therapies (CFTR modulators)

4. **Non-pharmacological Interventions:** Renewed focus on airway clearance, pulmonary rehabilitation, and digital health solutions

5. **Global Collaboration:** International registries (BRIDGE, COPD Foundation) facilitating large-scale research and phenotyping

6. **Research Gaps:** Limited data on long-term outcomes, optimal combination therapies, and treatment sequencing

7. **Emerging Paradigms:** Integration of traditional and complementary medicine, particularly in Asian populations

---

## Recommendations for Future Research

1. Head-to-head comparisons of antifibrotic agents
2. Combination therapy trials (antifibrotics + antimicrobials)
3. Long-term follow-up studies (>2 years)
4. Pediatric bronchiectasis therapeutic trials
5. Cost-effectiveness analyses of new therapies
6. Implementation science for digital health interventions
7. Biomarker validation for treatment response prediction
8. Registry linkage studies for real-world effectiveness

---
 
**Sources:** Europe PMC Database, ClinicalTrials.gov  
**Total Papers Reviewed:** 20  
**Total Active Trials:** 48
